- Home
- QVCG vs EQ Comparison
QVCG vs EQ Comparison
Compare QVCG & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QVCG | EQ |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.2M | 140.1M |
| IPO Year | 2003 | 2018 |
Fundamental Metrics
Financial Performance| Metric | QVCG | EQ |
|---|---|---|
| Price | $16.86 | $2.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 238.7K | ★ 412.1K |
| Earning Date | N/A | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,293,000,000.00 | $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.97 | $0.76 |
| 52 Week High | $18.32 | $3.54 |
Technical Indicators
Market Signals| Indicator | QVCG | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 59.82 | 56.40 |
| Support Level | $15.90 | $2.36 |
| Resistance Level | $18.00 | $2.58 |
| Average True Range (ATR) | 1.14 | 0.16 |
| MACD | 0.11 | 0.03 |
| Stochastic Oscillator | 57.41 | 85.90 |
Price Performance
Historical ComparisonAbout EQ Equillium Inc.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.